Abstract
Key messages
Curative treatment for sickle cell disease is potentially available to all patients using haematopoietic stem cell transplantation from alternative donors, but the risks of these procedures are very high
We don’t know when these high risk transplants should be offered to children or how parents should be counselled to give appropriate consent
In high income countries, non-transplant treatments are being developed for sickle cell disease that are likely to improve prognosis
We need to develop safer transplants and to explore the ethics of offering high risk procedures to children with sickle cell disease and other chronic conditions
Curative treatment for sickle cell disease is potentially available to all patients using haematopoietic stem cell transplantation from alternative donors, but the risks of these procedures are very high
We don’t know when these high risk transplants should be offered to children or how parents should be counselled to give appropriate consent
In high income countries, non-transplant treatments are being developed for sickle cell disease that are likely to improve prognosis
We need to develop safer transplants and to explore the ethics of offering high risk procedures to children with sickle cell disease and other chronic conditions
| Original language | English |
|---|---|
| Article number | j5250 |
| Journal | BMJ (Clinical research ed.) |
| Volume | 359 |
| Early online date | 23 Nov 2017 |
| DOIs |
|
| Publication status | Published - 2017 |
Keywords
- Anemia, Sickle Cell/therapy
- Child
- Hematopoietic Stem Cell Transplantation/adverse effects
- Histocompatibility
- Humans
- Randomized Controlled Trials as Topic/methods
- Risk Assessment
- Tissue Donors